Woodworth, Kate R;
Moulia, Danielle;
Collins, Jennifer P;
Hadler, Stephen C;
Jones, Jefferson M;
Reddy, Sujan C;
Chamberland, Mary;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Bell, Beth P;
Daley, Matthew F;
Mbaeyi, Sarah;
Dooling, Kathleen;
Oliver, Sara E.
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...
Fleming-Dutra, Katherine E;
Wallace, Megan;
Moulia, Danielle L;
Twentyman, Evelyn;
Roper, Lauren E;
Hall, Elisha;
Link-Gelles, Ruth;
Godfrey, Monica;
Woodworth, Kate R;
Anderson, Tara C;
Rubis, Amy B;
Shanley, Edwin;
Jones, Jefferson M;
Morgan, Rebecca L;
Brooks, H. Oliver;
Talbot, Keipp;
Lee, Grace M;
Bell, Beth P;
Meyer, Sarah;
Daley, Matthew;
Oliver, Sara E.
On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) amendments for the mRNA-1273 (Moderna) COVID-19 vaccine for use in children aged 6 months–5 years, administered as 2 doses (25 µg [0.25 mL] each), 4 weeks apart, and BNT162b2 (Pfizer-BioNTech) COVID-19 va...
Wallace, Megan;
Moulia, Danielle;
Blain, Amy E;
Ricketts, Erin K;
Minhaj, Faisal S;
Link-Gelles, Ruth;
Curran, Kathryn G;
Hadler, Stephen C;
!Asif, Amimah;
Godfrey, Monica;
Hall, Elisha;
Fiore, Anthony;
Meyer, Sarah;
Su, John R;
Weintraub, Eric;
Oster, Matthew E;
Shimabukuro, Tom T;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Bell, Beth P;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Daley, Matthew F;
Oliver, Sara E.
The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food a...
Oliver, Sara E;
Wallace, Megan;
See, Isaac;
Mbaeyi, Sarah;
Godfrey, Monica;
Hadler, Stephen C;
Jatlaoui, Tara C;
Twentyman, Evelyn;
Hughes, Michelle M;
Rao, Agam K;
Fiore, Anthony;
Su, John R;
Broder, Karen R;
Shimabukuro, Tom;
Lale, Allison;
Shay, David K;
Markowitz, Lauri E;
Wharton, Melinda;
Bell, Beth P;
Brooks, Oliver;
McNally, Veronica;
Lee, Grace M;
Talbot, H. Keipp;
Daley, Matthew F.
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...
Wu, Lei;
Chen, Yaolong;
Ma, Yanfang;
Yang, Zifeng;
Yang, Nan;
Denga, Wenze;
Chen, Yuanbin;
Sun, Yuanyuan;
Li, Yimin;
Lin, Lin.
Influenza is a major public health problem worldwide. Mutations and resistance development make the use of antiviral therapy challenging. Chinese patent medicines are often used to treat influenza in China and well tolerable. However, the misuse of Chinese patent medicines is common. We therefore aimed t...
Rochwerg, Bram;
Agarwal, Arnav;
Zeng, Linan;
Leo, Yee-Sin;
Appiah, John Adabie;
Agoritsas, Thomas;
Bartoszko, Jessica;
Brignardello-Petersen, Romina;
Ergan, Begum;
Ge, Long;
Geduld, Heike;
Gershengorn, Hayley B;
Manai, Hela;
Huang, Minhua;
Lamontagne, François;
Kanda, Seema;
Kawano-Dourado, Leticia;
Kurian, Linda;
Kwizera, Arthur;
Murthy, Srinivas;
Qadir, Nida;
Siemieniuk, Reed;
Silvestre, Maria Asuncion;
Vandvik, Per Olav;
Ye, Zhikang;
Zeraatkar, Dena;
Guyatt, Gordon.
Clinical question: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. Aft...
Tacconelli, E;
Mazzaferri, F;
Smet, A.M. de;
Bragantini, D;
Eggimann, P;
Huttner, B. D;
Kuijper, E. J;
Lucet, J. C;
Mutters, N. T;
Sanguinetti, M;
Schwaber, M. J;
Souli, M;
Torre-Cisneros, J;
Price, J. R;
Rodríguez-Bano, J.
The aim of these guidelines is to provide recommendations for decolonizing regimens targeting
multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings.
Methods: These evidence-based guidelines were produced after a systematic review of published studies
on decolonization intervention...
Infecciones por Bacterias Gramnegativas/diagnóstico,
Infecciones por Bacterias Gramnegativas/prevención & control,
Infecciones por Bacterias Gramnegativas/transmisión,
Política Informada por la Evidencia,
Infecciones por Enterobacteriaceae/prevención & control,
Infecciones por Enterobacteriaceae/transmisión,
Infecciones por Enterobacteriaceae/diagnóstico,
Resistencia a las Cefalosporinas/efectos de los fármacos,
Cefalosporinas/uso terapéutico,
Aminoglicósidos/uso terapéutico,
Fluoroquinolonas/uso terapéutico,
Trasplante de Microbiota Fecal/instrumentación
